Downgrades Mkt Outperform Mkt Perform X

MGNX MacroGenics

JMP Securities

Downgrades Buy Neutral X

MGNX MacroGenics

BTIG Research

Downgrades Buy Neutral X

MGNX MacroGenics

B. Riley Securities

$18 $5

Downgrades Buy Neutral X

MGNX MacroGenics

Guggenheim

Downgrades Outperform Mkt Perform X

MGNX MacroGenics

BMO Capital Markets

$24 $8

Downgrades Buy Hold X

MGNX MacroGenics

Stifel

$29 $7

Downgrades Buy Hold X

MGNX MacroGenics

TD Cowen

Initiated Buy X

MGNX MacroGenics

B. Riley Securities

$25

Upgrades Hold Buy X

MGNX MacroGenics

TD Cowen

Reiterated Buy X

MGNX MacroGenics

BTIG Research

$12 $24

Downgrades Buy Neutral X

MGNX MacroGenics

H.C. Wainwright

$12 $14

Upgrades Neutral Buy X

MGNX MacroGenics

Guggenheim

$12

Downgrades Buy Neutral X

MGNX MacroGenics

Guggenheim

Downgrades Outperform Mkt Perform X

MGNX MacroGenics

Cowen

Upgrades Mkt Perform Outperform X

MGNX MacroGenics

BMO Capital Markets

$5.70 $16

Downgrades Outperform Neutral X

MGNX MacroGenics

SMBC Nikko

$5

Downgrades Outperform Mkt Perform X

MGNX MacroGenics

BMO Capital Markets

$31 $4

Downgrades Buy Neutral X

MGNX MacroGenics

Guggenheim

Initiated Outperform X

MGNX MacroGenics

BMO Capital Markets

$31

Initiated Outperform X

MGNX MacroGenics

SMBC Nikko

$40

Resumed Buy X

MGNX MacroGenics

Guggenheim

$30

Initiated Mkt Outperform X

MGNX MacroGenics

JMP Securities

$39

Resumed Buy X

MGNX MacroGenics

BTIG Research

$50

Resumed Outperform X

MGNX MacroGenics

Credit Suisse

$37

Upgrades Underweight Overweight X

MGNX MacroGenics

Barclays

$14 $40

Resumed Buy X

MGNX MacroGenics

H.C. Wainwright

$36

Upgrades Neutral Outperform X

MGNX MacroGenics

Wedbush

$26

Initiated Neutral X

MGNX MacroGenics

Guggenheim

Upgrades Sell Buy X

MGNX MacroGenics

Citigroup

Downgrades Outperform Neutral X

MGNX MacroGenics

Wedbush

Downgrades Neutral Sell X

MGNX MacroGenics

Citigroup

$10

Downgrades Outperform Underperform X

MGNX MacroGenics

Raymond James

Resumed Buy X

MGNX MacroGenics

BTIG Research

$30

Initiated Outperform X

MGNX MacroGenics

Evercore ISI

$33

Initiated Buy X

MGNX MacroGenics

H.C. Wainwright

$38

MGNX  MacroGenics, Inc.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.